In a world first, a new prostate cancer therapy drug developed by Australian start-up AdvanCell has been administered to its first patient in a clinical trial, supported by NIF at Herston Imaging Research Facility.
Supporting NIF Partner
In a world first, a new prostate cancer therapy drug developed by Australian start-up AdvanCell has been administered to its first patient in a clinical trial, supported by NIF at Herston Imaging Research Facility.